DCU
NVO

Dara Capital US’s Novo Nordisk NVO Stock Holding History

Dara Capital US’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$222K Hold
4,630
– – 0.15% 75
2026
Q1 		$170K Hold
4,630
– – 0.16% 83
2025
Q4 		$236K Buy
+4,630
New +$237K 0.21% 77

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Dara Capital US's NVO Position: Q2 2026 in Review

Dara Capital US held its Novo Nordisk (NVO) position steady in Q2 2026 at 4,630 shares worth $222K. The position accounts for 0.15% of the portfolio, ranked #75.

Dara Capital US first reported a position in NVO in Q4 2025 and has held it in 3 quarters since. The position peaked at $236K in Q4 2025. 1,346 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Dara Capital US held 4,630 shares of Novo Nordisk worth $222K as of Q2 2026.
  • Dara Capital US left its Novo Nordisk share count unchanged in Q2 2026.
  • Novo Nordisk made up 0.15% of Dara Capital US's portfolio in Q2 2026, its #75 holding.
  • Dara Capital US first reported a position in Novo Nordisk in Q4 2025 and has held it in 3 quarters since.
  • Dara Capital US's Novo Nordisk position peaked at $236K in Q4 2025.
  • 1,346 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Dara Capital US's 13F filing for Q2 2026, filed 23 Jul 2026.